Diligence memo · auto-generated · as of July 2, 2026
U.S. Stem Cell, Inc.
U.S. Stem Cell, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
U.S. Stem Cell, Inc. operates in Other Health Care, based in SUNRISE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
U.S. Stem Cell, Inc. has raised $1.6M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $468K on 2013-03-04.
Most recent recorded round closed around 2021-02-17.
Valuation (modeled)modeled
Provath models U.S. Stem Cell, Inc. at approximately $4.3M (range $119K–$40M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.53× the median modeled value of Pre-Seed Other Health Care companies in 2019–2021 (295 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 21 months.
Last raise 5.4 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.7× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 43% of Other Health Care peers (5377 compared).
Modeled value ranks above 18% of those peers.
Closest niche peers: Aetas Co LLC, Hauppauge SC Holdings, LLC, Gateway IV Lithotripsy, LLC, Endoscopy Center of West Central Ohio, LLC, Dalent LLC.
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.